Julie A. Jurgens

Julie A. Jurgens

Auto-generated profile, based on publicly available information

Julie A. Jurgens

Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
JJJulie Jurgens
Julie Jurgens
HLHua Ling
Hua Ling
KHKurt Hetrick
Kurt Hetrick
EPElizabeth Pugh
Elizabeth Pugh
FSFrancois Schiettecatte
Francois Schiettecatte
NSNara Sobreira
Nara Sobreira
In March 2013 the American College of Medical Genetics and Genomics published a list of 56 genes with the recommendation that pathogenic and likely pathogenic variants detected incidentally by clinical sequencing be reported to patients. As an initial step in determining the practical consequences of this recommendation in the research setting, we searched for variants in these genes in 232 whole-exome sequences from the Baylor-Hopkins Center for Mendelian Genomics. We identified rare, nonsynonymous, and splicing single-nucleotide variants and insertions/deletions and assessed variant classification using the Human Gene Mutation, Emory, and ClinVar databases. We analyzed the burden of mutation in each of the 56 genes and determined which variants should be reported to patients. Our filtering resulted in 249 distinct variants, with a mean of 1.69 variants per individual. Half of these were novel missense mutations not classified by any of the three reference databases. Of 101 variants listed in the Human Gene Mutation Database, 48 were also in ClinVar and 3 were also in Emory; half of these shared variants were classified discordantly between databases. Some genes consistently had greater variation than others. In total, 0.86% of individuals had a reportable incidental variant. These observations demonstrate some current challenges of assessing phenotypic consequences of incidental variants for counseling patients. Genet Med 17 10, 782–788.

17 July 2024 in Genetics in Medicine
Verified
Journal Article
Open access
JJJulie A Jurgens
Julie A Jurgens
BBBrenda J Barry
Brenda J Barry
WCWai-Man Chan
Wai-Man Chan
SMSarah MacKinnon
Sarah MacKinnon
MWMary C Whitman
Mary C Whitman
EEElizabeth C Engle
Elizabeth C Engle
This study aimed to identify genetic etiologies and genotype/phenotype associations for unsolved ocular congenital cranial dysinnervation disorders (oCCDDs). We coupled phenotyping with exome or genome sequencing of 467 probands (550 affected and 1108 total individuals) with genetically unsolved oCCDDs, integrating analyses of pedigrees, human and animal model phenotypes, and de novo variants to identify rare candidate single-nucleotide variants, insertion/deletions, and structural variants disrupting protein-coding regions. Prioritized variants were classified for pathogenicity and evaluated for genotype/phenotype correlations. Analyses elucidated phenotypic subgroups, identified pathogenic/likely pathogenic variant(s) in 43 of 467 probands (9.2%), and prioritized variants of uncertain significance in 70 of 467 additional probands (15.0%). These included known and novel variants in established oCCDD genes, genes associated with syndromes that sometimes include oCCDDs (eg, MYH10 [HGNC:7568], KIF21B [HGNC:29442], TGFBR2 [HGNC:11773], and TUBB6 [HGNC:20776]), genes that fit the syndromic component of the phenotype but had no prior oCCDD association (eg, CDK13 [HGNC:1733], TGFB2 [HGNC:11768]), genes with no reported association with oCCDDs or the syndromic phenotypes (eg, TUBA4A [HGNC:12407], KIF5C [HGNC:6325], CTNNA1 [HGNC:2509], KLB [HGNC:15527], FGF21 [HGNC:3678]), and genes associated with oCCDD phenocopies that had resulted in misdiagnoses. This study suggests that unsolved oCCDDs are clinically and genetically heterogeneous disorders often overlapping other Mendelian conditions and nominates many candidates for future replication and functional studies.

7 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MSMugdha Singh
Mugdha Singh
SSSarah L. Stenton
Sarah L. Stenton
EGEmily Groopman
Emily Groopman
MSMoriel Singer-Berk
Moriel Singer-Berk
JMJialan Ma
Jialan Ma
SGSanna Gudmundsson
Sanna Gudmundsson
INTRODUCTION: Despite major advances in genomic sequencing and analytical pipelines for rare disorders, more than 50% of affected individuals remain without a molecular diagnosis. One challenge is the interpretation of inherited variants exhibiting incomplete penetrance (IP). MATERIALS AND METHODS: We developed a pipeline to systematically investigate inherited variants as the cause of rare disease in 4,325 families, consisting of affected probands and unaffected parents, from the Broad Center for Mendelian Genomics, part of the GREGoR Consortium. As a proof-of-concept of further omics follow-up, epigenomic and transcriptomic analyses were performed in one family harboring an inherited disease-causing frameshift variant in CHD8 . RESULTS: We identified 81 families where the affected proband harbored a putative disease-causing variant inherited from a reportedly unaffected parent. Clinical re-evaluation identified 30 families in which an inherited variant was considered diagnostic, including six previously missed diagnoses. In this cohort, inherited IP variants account for 1.6% of the diagnosed cases, with an overall diagnostic yield of 0.4% in the cohort. Methylation analysis of the CHD8 family confirmed a positive CHD8 clinical episignature in the male proband, but also in the reportedly unaffected mother. Transcriptomic analysis showed that despite similar CHD8 haploinsufficiency, the proband and mother displayed divergent downstream transcriptional effects. DISCUSSION: This study highlights the importance of considering parentally inherited IP variants in rare disease, with at least 1 in 60 diagnostic variants inherited from a reportedly unaffected parent, and demonstrates the potential of integrating omics evaluation to improve variant interpretation.

12 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JJJulie A. Jurgens
Julie A. Jurgens
ABAndreas Bueckle
Andreas Bueckle
JVJeet Vora
Jeet Vora
MMMano R. Maurya
Mano R. Maurya
TATaha Mohseni Ahooyi
Taha Mohseni Ahooyi
CGCasey S. Greene
Casey S. Greene
Summary: The NIH Common Fund Data Ecosystem (CFDE) integrates data resources from 18 NIH Common Fund programs for discovery and integrative analysis. These programs generate valuable but heterogeneous datasets that can be difficult to discover, access, and reuse. CFDE aims to provide a collaborative, community-built infrastructure that links and enriches Common Fund programs. We describe the evolution, structure, and core technologies of CFDE, including practical approaches that support submission, integration, visualization, and public release of multimodal data. Training programs and workforce initiatives lower barriers to adoption. CFDE has devised solutions to critical issues facing cross-program initiatives, including data scale and heterogeneity, dataset integration, and long-term sustainability. We demonstrate the utility of linking Common Fund resources through integrative tools and cross-dataset queries to yield insights that would otherwise be infeasible. Collectively, CFDE shows that a standards-driven, federated approach enhances and unifies cross-disciplinary resources, fostering collaboration and data-driven discovery.

15 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JJJulie A. Jurgens
Julie A. Jurgens
PRPaola M. Matos Ruiz
Paola M. Matos Ruiz
JKJessica King
Jessica King
EFEmma E. Foster
Emma E. Foster
LBLindsay Berube
Lindsay Berube
EEElizabeth C Engle
Elizabeth C Engle
Purpose: To functionally evaluate novel human sequence-derived candidate genes and variants for unsolved ocular congenital cranial dysinnervation disorders (oCCDDs). Methods: Through exome and genome sequencing of a genetically unsolved human oCCDD cohort, we previously identified variants in 80 strong candidate genes. Here, we further prioritized a subset of these (43 human genes, 57 zebrafish genes) using a G0 CRISPR/Cas9-based knockout assay in zebrafish and generated F2 germline mutants for seventeen. We tested the functionality of variants of uncertain significance in known and novel candidate transcription factor-encoding genes through protein binding microarrays. Results: We first demonstrated the feasibility of the G0 screen by targeting known oCCDD genes phox2a and mafba . 70-90% of gene-targeted G0 zebrafish embryos recapitulated germline homozygous null-equivalent phenotypes. Using this approach, we then identified three novel candidate oCCDD genes ( SEMA3F , OLIG2, and FRMD4B ) with putative contributions to human and zebrafish cranial motor development. In addition, protein binding microarrays demonstrated reduced or abolished DNA binding of human variants of uncertain significance in known and novel sequence-derived transcription factors PHOX2A (p.(Trp137Cys)), MAFB (p.(Glu223Lys)), and OLIG2 (p.(Arg156Leu)). Conclusions: This study nominates three strong novel candidate oCCDD genes ( SEMA3F , OLIG2, and FRMD4B ) and supports the functionality and putative pathogenicity of transcription factor candidate variants PHOX2A p.(Trp137Cys), MAFB p.(Glu223Lys), and OLIG2 p.(Arg156Leu). Our findings support that G0 loss-of-function screening in zebrafish can be coupled with human sequence analysis and protein binding microarrays to aid in prioritizing oCCDD candidate genes/variants.

3 November 2026 in Patterns
Verified
Journal Article
Open access
JJJulie A. Jurgens
Julie A. Jurgens
ABAndreas Bueckle
Andreas Bueckle
JVJeet Vora
Jeet Vora
MMMano R. Maurya
Mano R. Maurya
TATaha Mohseni Ahooyi
Taha Mohseni Ahooyi
CGCasey S. Greene
Casey S. Greene